biostudies-literatureRescigno MMinistero della Salute1104124https://www.ebi.ac.uk/biostudies/studies/S-EPMC9911671biostudies-literatureUnknown14<h4>Introduction</h4>Immunocompromised patients have been shown to have an impaired immune response to COVID-19 vaccines.<h4>Methods</h4>Here we compared the B-cell, T-cell and neutralizing antibody response to WT and Omicron BA.2 SARS-CoV-2 virus after the fourth dose of mRNA COVID-19 vaccines in patients with hematological malignancies (HM, n=71), solid tumors (ST, n=39) and immune-rheumatological (IR, n=25) diseases. The humoral and T-cell responses to SARS-CoV-2 vaccination were analyzed by quantifying the anti-RBD antibodies, their neutralization activity and the IFN-γ released after spike specific stimulation.<h4>Results</h4>We show that the T-cell response is similarly boosted by the fourth dose across the different subgroups, while the antibody response is improved only in patientsFrontiers in immunologyNeutralizing antibodies to Omicron after the fourth SARS-CoV-2 mRNA vaccine dose in immunocompromised patients highlight the need of additional boosters.PMC9911671Ricerca Corrente 2021-Special Projects-VAX4FRAILPozzi CSalvarani CDagna LTrinca SBarberini AMotta FFilippi MTurola ENitti RPantaleo MAMarchesi FMerli FCasetti RGirardi ECatanoso MGCiceri FStefoni VRubino MDivella RFrancalancia MGarrisi VLeone SCiliberto GFondazione RMMatusali GConti LAgrati CCastilletti CFornasa GFrangiamore SBRDi Cosimo SMiggiano CLaroni AAzzolini EGermagnoli LCeribelli ALizier MBaldanti FAntozzi CGili SStanghellini MTLMorrone AGramigna GNotari STartaglia EGoletti DCarsetti RMortarini RPapa EUccelli AMengarelli AApolone GLapucci CQuintarelli CBettini AMantovani ASinno VGuberti Mde Braud FLazzarotto TCatalano GTufaro AMeschi SPiaggio GTommasino MPinter GLDamian SCimini EGenova CSilvestris NFenoglio DCristofanelli FPoire ICassaniti ICostantini MMiano MVAX4FRAIL study GroupMassafra RDal Bello MGRescigno MMinuti GPEGDelcuratolo SBruno AGiannarelli DPinto CCorazza SFusconi MMontecucco CMGraceffa DPulice IOgliari FMonti SColavita FElena RBertuzzi AMandoj CLocatelli FCorradini PCroci SBaggi FInglese MBonifazi FLapa DValzania FMariotti DSelmi CBordoni VMaggi LSacchi ADe Santis MMarasco VPronzato PCarlo-Stella CPuro EGrassi GBortone FZinzani PLLupo-Stanghellini MTfalseNeutralizing antibodies to Omicron after the fourth SARS-CoV-2 mRNA vaccine dose in immunocompromised patients highlight the need of additional boosters.<h4>Introduction</h4>Immunocompromised patients have been shown to have an impaired immune response to COVID-19 vaccines.<h4>Methods</h4>Here we compared the B-cell, T-cell and neutralizing antibody response to WT and Omicron BA.2 SARS-CoV-2 virus after the fourth dose of mRNA COVID-19 vaccines in patients with hematological malignancies (HM, n=71), solid tumors (ST, n=39) and immune-rheumatological (IR, n=25) diseases. The humoral and T-cell responses to SARS-CoV-2 vaccination were analyzed by quantifying the anti-RBD antibodies, their neutralization activity and the IFN-γ released after spike specific stimulation.<h4>Results</h4>We show that the T-cell response is similarly boosted by the fourth dose across the different subgroups, while the antibody response is improved only in patients2023-01-01T00:00:00Z20232026-07-14T21:07:26.947Z2025-04-06T07:57:16.361ZS-EPMC99116713677685310.3389/fimmu.2023.1104124